Equine malignant hyperthermia (EMH)
Equine malignant hyperthermia (EMH)
General description
Equine Malignant Hyperthermia (EMH) is a life-threatening pharmacogenetic disorder of skeletal muscle elicited by halogenated anesthetics, depolarizing muscle relaxants, and stress. Clinical and laboratory manifestations include tachycardia, hyperthermia, muscle rigidity, rhabdomyolysis, respiratory and metabolic acidosis, and electrolyte derangements.
Breeds
Appaloosa, Paint Horse, Quarab, Quarter Horse, Quarter pony
Order details
| Test number | 8160 |
| Abbreviation | EMH |
| Sample material | 0.5 ml EDTA blood, mane/tail hair roots |
| Test duration | 3-5 working days |
Test specifications
| Symptom complex | systemic |
| Inheritance | autosomal dominant |
| Causality | causally |
| Literature | OMIA:000621-9796 |
Detailed description
Equine Malignant Hyperthermia (EMH) is a life-threatening pharmacogenetic disorder of skeletal muscle elicited by halogenated anesthetics, depolarizing muscle relaxants, and stress. Dysfunction of RyR1 (calcium release channel of the sarcoplasmic reticulum of skeletal muscle) results in excessive release of calcium into the myoplasm-triggering cascade events that lead to a hypermetabolic state and ultimately cell death. Clinical and laboratory manifestations include tachycardia, hyperthermia, muscle rigidity, rhabdomyolysis, respiratory and metabolic acidosis, and electrolyte derangements.
